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ABCB4 is an ATP-binding cassette transporter that extrudes phosphatidylcholine into the bile canaliculi 
of the liver. Its dysfunction or inhibition by drugs can cause severe, chronic liver disease or drug-induced 
liver injury. The molecular mechanisms underpinning the physiological function of ABCB4 and its 
inhibition by small-molecule compounds are unknown. We determined the cryo-EM structure of 
nanodisc-reconstituted human ABCB4 trapped in an ATP-bound state at a resolution of 3.2 Å. The 
nucleotide-binding domains form a closed conformation containing two bound ATP molecules, but only 
one of the ATPase sites contained bound Mg2+. The transmembrane domains adopt a collapsed 
conformation at the level of the lipid bilayer, but we observed a large, hydrophilic, and fully occluded 
cavity at the level of the cytoplasmic membrane boundary, with no ligand bound. This indicates a state 
following substrate release but prior to ATP-hydrolysis. Mutational analysis suggested a surprising, 
essential role of the extracellular loops in phosphatidylcholine transport. We further identified three 
residues on transmembrane helix 12 that are critical for function and may be involved in substrate 
recognition. Our results rationalize disease-causing mutations in human ABCB4 and provide evidence 
for an ‘alternating access’ mechanism of lipid extrusion, distinct from the ‘credit card swipe’ model of 
other lipid flippases and scramblases.  
 
The ATP-binding cassette (ABC) transporter ABCB4 is a phospholipid translocator critical for bile 
generation1-3. It is expressed mainly in hepatocytes4,5 and trafficked to the apical membranes forming the 
boundary to bile canaliculi. ABCB4 actively exports phosphatidylcholine (PC) into the bile and its functional 
role is closely connected with the functions of two other ABC transporters, the bile salt export pump BSEP 
(ABCB11) and the cholesterol transporter ABCG5/G82,3. The PC extrusion of ABCB4 is stimulated by 
canalicular bile salts (exported by ABCB11) and in turn stimulates the cholesterol export mediated by 
ABCG5/G8. Balancing these three transport processes is essential to guarantee the correct ratio of bile 
constituents forming mixed micelles, which in turn is important to protect the liver and bile ducts from the 
detergent-like activity of bile salts1-3 (Fig. 1a).  
Several mutations in the ABCB4 gene are known to cause progressive familial intrahepatic cholestasis 
(PFIC) type 3, a severe liver disease6. Less severe, or shorter term, functional impairments of ABCB4 are 
associated with higher risk of gall stones, intrahepatic cholestasis of pregnancy and are a risk factor for 
developing cholangitis6-8. Several ABCB4 mutations have been studied in cellular assays and in sufficient 
detail to distinguish whether they affect the function of the transporter or either protein expression or 
trafficking(9-15). In addition to genetic mutation, ABCB4 can be inhibited by pharmaceutical compounds, 
which can cause drug-induced liver injury (DILI)16,17. Several marketed drugs with DILI risk profiles inhibit 
ABCB4 in cellular assays18-20, and ABCB4 inhibition by Itraconazole has been shown to cause cholestasis in 
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rats21. Further, genomic studies suggest a link between ABCB4 dysfunction and hepatobiliary 
malignancies22-25, and it has been reported that ABCB4 is frequently epigenetically silenced in cancer26.  
Despite its importance in health and disease, no high-resolution structure of ABCB4 is currently available. 
Furthermore, the significant mechanistic diversity within the ABC transporter family make mechanistic 
inferences based on other ABC transporters problematic in the absence of direct structural data27. ABCB4 
has been proposed to work by ‘flopping’ PC molecules from the inner to the outer membrane leaflet28,29, 
where the resulting excess of outer leaflet PC is released into canalicular bile in a process facilitated by 
canalicular bile salts30. However, it is not known how ABCB4 achieves the translocation and reorientation 
of PC or whether the release of PC is into the outer membrane leaflet or directly into bile. Furthermore, 
other ABC transporters of lipidic substrates traffic these in a variety of ways, with distinct mechanisms 
proposed for MsbA31, PglK32, and ABCA133. 
When first discovered, ABCB4 was assumed to be a multi-drug exporter due to its high sequence 
conservation (76% identity, 86% similarity) to ABCB134 (P-glycoprotein), and ABCB4 is still often referred 
to as multidrug-resistance-protein 3 (MDR3). However, while various studies have shown ABCB4 to be 
capable of recognizing and transporting some ABCB1 substrates (albeit with low capacity)35,36, the data 
regarding its role in conferring drug resistance is inconclusive37-40. Similarly, ABCB1 has only been shown 
to flip short-chain, fluorescently labelled lipid analogues in cellular assays41, and despite its canalicular 
expression3, ABCB1 is unable to compensate for loss of ABCB4 function1. Consequently, it is now accepted 
that despite their high sequence identity, ABCB4 and ABCB1 are functionally distinct proteins2,42. However, 
while multiple structures of ABCB1 have been reported and have increased our mechanistic understanding 
of multi-drug export43-46, they are insufficient to decipher the molecular details of ABCB4-catalyzed 
phosphatidylcholine transport. Direct visualization of ABCB4 has been challenging, partly due to difficulties 
in obtaining suitable amounts of functional and pure ABCB447, possibly stemming from toxicity induced by 
its overexpression in mammalian cells48. This has also hampered efforts at purifying the protein, likely 
explaining the limited number of in vitro studies on purified ABCB442,49,50.  
In order to address the lack of mechanistic insight into ABCB4 function, rationalize disease-causing 
mutations, and lay the groundwork for structure-guided therapeutic strategies, we purified ABCB4 from 
human cells and determined its structure at a resolution of 3.2Å. This allowed us to generate structure-
guided chimeras between ABCB4 and ABCB1, which in turn allowed us to identify key differences 
responsible for the functional distinction between the two transporters. Based on these results we 
propose that ABCB4 employs an ‘alternating access’ mechanism for PC translocation, with an important 





Functional characterization of ABCB4  
For ABCB4 expression, we generated a tetracycline-inducible, stable HEK293 cell line, where the function 
of expressed hABCB4 could be tested in a cellular PC extrusion assay. To mimic the physiological conditions 
of endogenous ABCB4, taurocholate was added to stimulate PC transport, and BSA was added as an 
acceptor of extruded lipids. (Fig. 1a-b). While this assay does not replicate the polarity of hepatocytes or 
the complexity of bile that contains mixed micelles consisting of an array of bile salts and PC, we were able 
to demonstrate that PC extrusion in our ABCB4-generating cell line was dependent on induction of ABCB4 
expression, and that PC extrusion was stimulated more than two-fold by the presence of taurocholate (Fig. 
1b). The extrusion activity was completely absent in a similar cell line expressing ABCB4 with glutamate to 
glutamine (EQ) mutations in both Walker-B motifs51. These EQ mutations strongly reduce the ATPase 
activity of ABC transporters and allow trapping them in a pre-hydrolytic state52. The absence of PC 
extrusion by ABCB4[EQ] despite higher protein yields over wildtype ABCB4 (Supp. Fig. 1), demonstrated 
that the ABCB4-mediated PC extrusion we observed was dependent on sustained ATP hydrolysis.  
ABCB4 extracted from the membrane and purified in detergent micelles displayed very low ATPase activity 
(Fig. 1d, red line). Earlier studies arriving at similar results led to the proposal that low-efficiency, low-
affinity transport may be an adaptation to the special circumstances of ABCB4 in the canaliculi35,47, where 
the protein is essentially suspended in its own substrate. However, other studies have found ample ATPase 
activity of ABCB415,50. We reconstituted detergent-purified ABCB4 into nanodiscs containing a mixture of 
liver polar lipids and cholesteryl hemisuccinate (Fig. 1c, Supp. Fig. 1c-f) and recovered robust ATP 
hydrolysis activity, with Vmax in the range of 80-130 nmol ATP min-1 mg-1 and Km for ATP in the range of 0.6-
1.2mM (Fig. 1d blue curve), lower than the 200-400 nmol ATP min-1 mg-1 found for nanodisc-reconstituted 
ABCB145. Similar to ABCB153, the ATPase activity of ABCB4 was all but abolished by addition of ortho-
vanadate (Supp. Fig. 2a), and we found little to no activity for ABCB4[EQ] in detergent or in nanodiscs (Fig. 
1e). Our results demonstrate that the environment of human ABCB4 is critical for its activity, perhaps due 
to the presence of PC in the nanodiscs, which suggests that nanodisc-reconstituted ABCB4 is in a 
physiologically relevant state for structural studies. 
 
Cryo-EM structure determination of ATP-bound ABCB4[EQ] 
Our first attempts at determining the structure of ABCB4 were performed using nanodisc reconstituted 
wild-type protein stabilized by vanadate-trapping. However, the resulting reconstructions displayed low 
resolution that did not allow transmembrane helices to be unambiguously resolved, while multiple NBD 
conformations with varying degrees of NBD closure were observed (Supp. Fig. 2b-d). We concluded that 
there was high conformational flexibility and residual movement in the protein despite the vanadate 
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trapping, and that another approach for conformational stabilization was necessary. We next studied 
nanodisc-reconstituted ABCB4[EQ] in the presence of 5mM ATP-Mg2+ (Supp. Fig. 3a). The resulting 2D and 
3D class averages showed that a majority of particles adopted a closed NBD conformation (Supp. Fig. 3b). 
However, a significant minority adopted a state resembling the ‘inward open’ conformation, the density 
of which was visibly worse than that of the closed conformation (Supp. Fig. 3b). The fraction of particles in 
the open conformation (29%) is reasonably close to the value of ~10-20% unoccupied particles expected 
for a protein with a Km of 0.6-1.2 mM in the presence of 5mM ATP-Mg2+, assuming a Hill slope of one in 
the Hill-Langmuir equation. The discrepancy could suggest that the true Hill-slope has a slightly different 
value due to the presence of two ATP binding sites in the transporter. Particles showing closed NBDs were 
used to obtain a 3D reconstruction at a resolution of 3.2Å as judged by the FSC curve using the 0.143 
cutoff54 (Supp. Fig. 3c), allowing for unambiguous side chain placement for most of the protein (Supp. Fig. 
4).   
 
The ‘closed conformation’ of ABCB4[EQ] is incompatible with substrate binding 
The structure of ABCB4[EQ] in a nucleotide-bound state (Fig.2 a-b) is characterized by extensive contacts 
between the two halves of the transporter along the entire vertical axis (perpendicular to the membrane) 
(Fig. 2b-c). The transmembrane domains (TMDs) are surrounded by two rings of ordered cholesterol 
molecules bound to lipid-exposed surface grooves, forming both hydrogen bonds and aromatic stacking 
(Fig. 2b), reminiscent of interaction patterns observed for nanodisc-reconstituted ABCB145. At the level of 
the lipid bilayer, the TMDs adopted a collapsed conformation, with no cavity visible. In contrast, a large 
hydrophilic cavity was observed at the boundary of the inner leaflet, extending into the cytoplasmic 
regions of the TMDs. This cavity is completely closed off from the intracellular matrix and from the 
extracellular domain of ABCB4 (Fig. 2c). Despite the size of this cavity (3756 Å3 estimated in Caver55 with a 
probe size of 1.4Å) no extraneous density was found inside (size of a PC molecule, PC7 from PDBeChem56, 
estimated at 782 Å3 in UCSF Chimera57). The hydrophilic nature and the location mainly below the 
membrane level make this pocket an unlikely site for lipidic substrate binding. However, it may provide a 
site for binding inhibitors or modulators of ABCB4.  
The absence of any opening of the hydrophobic interior to either side of the membrane differentiates our 
structure from both the ‘inward-open’ conformation observed for several ABC transporters, including 
ABCB143, the ‘outward open’ conformation observed for Sav186658, and the occluded conformation 
observed for McjD59. The finding that ABCB4 is substrate-free despite the high concentration of substrate 
in the lipidic nanodisc suggests that the observed state is incompatible with substrate binding and that the 
ATP-triggered transition into this state is likely responsible for causing the extrusion of previously 
associated PC molecules. Our structure therefore indicates that transport of PC by ABCB4 precedes 
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hydrolysis and that the energy supplied by conversion of ATP to ADP is required to ‘reset’ the protein for 
the next transport cycle, suggesting an ‘ATP switch’ model51 for ABCB4 function, similar to what has been 
proposed for ABCB146 
 
Subtle asymmetry in interactions of NBDs with ATP-Mg2+ 
We observed strong and well-defined EM density for two bound ATP molecules sandwiched between the 
Walker-A motifs and the Signature motifs of opposing NBDs (Fig. 3a). At ATPase site 1 (defined as the site 
containing the Walker-A and Walker-B motifs of NBD2 and the Signature Motif of NDB1), clear density is 
observed for bound ATP-Mg2+, with the magnesium ion mediating strong contacts between the beta and 
gamma phosphates of ATP and residues S1076 (in the Walker A motif) and the Q-loop glutamine, Q1117, 
near the Signature motif of NBD1 (Fig. 3a, right insert). In contrast, the other ATPase site (site 2, Fig. 3a, 
left insert) shows no density for a bound magnesium ion, and the gamma phosphate moiety of bound ATP 
is shifted towards Q477 and S436 (Fig. 3b). The density for these residues and for the gamma phosphate 
group of ATP are slightly weaker than the equivalent densities in ATPase site 1, suggesting that bound Mg2+ 
helps orient and immobilize the phosphate groups. Another possible interpretation of the observed 
asymmetry would be that instead of ATP, ADP-Mg2+ could be bound at the ATPase site 2. However, this 
would imply that during sample preparation, all ATP at site 2 had been hydrolysed. However, given the 
near absence of hydrolysis of the ABCB4[EQ] sample, it is much more likely that ATP is bound at site 2. We 
also observe asymmetry in the so-called H-loops containing the conserved H589 (near site 1) and H1231 
(near site 2). Equivalent histidines have been shown to be essential for ATP hydrolysis in the ABC 
transporter HlyB60. While the different conformations of H589 and H1231 of ABCB4 do not appear to affect 
the overall structure of the NBDs, they might influence hydrolysis and be in part responsible for the 
significantly lower ATPase rates of ABCB4 compared with ABCB1. 
While asymmetry is an intrinsic feature in heterodimeric ABC transporters that contain one consensus and 
one degenerate ATPase site27, it has also been proposed to be relevant for transporters containing two 
functional ATPase sites including ABCB161, where nucleotide trapping experiments suggest that hydrolysis 
occurs at both sites but does not occur simultaneously52,62. Remarkably, no asymmetry was observed in 
the nucleotide-bound structure of ABCB1[EQ] or in other full-length ABC transporter structures featuring 
EQ mutations63-65. For ABCB1, this was ascribed to the use of an EQ-mutation and of saturating 
concentration of ATP-Mg2+ (10mM against a Km of 0.18mM)46. Thus, our ABCB4 structure is the first report 
of an ABC transporter containing two consensus ATPase sites but structural asymmetry at the ATPase sites 
of a double EQ variant. Our results may support the idea that even for ABC transporters with very similar 
NBDs such as ABCB1 and ABCB4, subtle but significant differences in how the NBDs interact with 
nucleotides may occur at lower saturation (5mM against a Km of 0.6-1.2mM). Since the average 
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intracellular concentration of ATP in rat liver has been estimated to be ~3.5mM66, the concentration used 
here may be close to the physiological working conditions of ABCB4. However, we cannot rule out that the 
asymmetry we observe is influenced by, or even caused by, the EQ mutations. The function of ABCB4 
containing a single EQ mutation (E558Q) has been investigated previously. The introduced mutation 
affected ATPase site 2, leaving site 1, where we observe bound Mg2+, unaltered. It was found that the 
single EQ mutation of ABCB4[E558Q] abolished the transport of PC10, demonstrating that the ATPase site 
where we find bound Mg2+ cannot drive transport alone. Unravelling the precise effects of this structural 
asymmetry, for example alternating hydrolysis, will likely require alternate conformations to be 
investigated at high resolution. 
 
Disease-causing mutations suggest mechanistic conservation between ABCB4 and ABCB1 
We used our structure to rationalize the array of known disease-causing ABCB4 mutations and as a starting 
point for functional studies of the molecular determinants of PC transport. The available literature9-15 
reported 15 unique positions where ABCB4 mutation did not significantly impair protein expression or 
maturation but did impair its function (Fig. 4a, Supp. Table 2), ranging in severity from moderate to 
complete impairment. Though the number of mutations under consideration is thus limited and mutations 
from patients suffering from PFIC appear predominant, some intriguing patterns emerged. A cluster of 
positions associated with functionally impairing, disease-causing mutations is seen in the NBDs (Fig. 4a, 
Supp. Fig. 6 for stereo view), with all these positions except A1186T less than 5Å from a bound nucleotide, 
suggesting that they interfere with ATP binding. In addition, 11 mutations were reported to impair 
expression, trafficking or maturation of ABCB4 (Fig. 4b, Supp. Fig. 6 for stereo view). They also display 
clustering in the NBDs but based on their location only G536R would be expected to disrupt ATP binding 
directly. This is particularly interesting because the PC secretion activity of the G536R mutation was 
partially rescued by the CFTR potentiator Ivacaftor, as was the functional impairment of the mutations 
G535D, S1076C, S1176L and S1178S. Our structure provides direct evidence of a previous proposal based 
on homology modelling that these mutations would all affect the nucleotide binding sites13, suggesting 
that the potential success of treatment of ABCB4 deficiency by Ivacaftor might be predicted based on 
knowledge of a patient’s genotype. 
For disease-causing mutations in the TMDs, three mutations (P726L, S346I and A286V) were reported to 
lead to more than 90% functional impairment, without affecting trafficking. They interact with residues in 
the core of ABCB4, which can explain why their disruption is particularly damaging. The remaining 
positions have side chains oriented towards the membrane or solvent-exposed areas and have less drastic 
effects on function when mutated. Interestingly, even P726, S346 and A286 are conserved in ABCB1, as 
are nearly all the positions where functionally impairing mutations are found, the exceptions being T34 
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and A737 (Supp. Fig. 5). This is surprising because it is precisely in their function that these two ABC 
transporters differ, but suggests that ABCB4 and ABCB1 achieve their distinct functions through a similar 
transport mechanism. 
 
ABCB4-ABCB1 chimeras reveal function-encoding regions of ABCB4 
In order to identify which protein regions are responsible for the distinct functions of ABCB4 and ABCB1, 
we generated ABCB4-ABCB1 chimeras and tested their function in cellular PC extrusion assays. Based on 
a sequence alignment (Supp. Fig. 5) superimposed on the structure of ABCB4, we identified three regions 
of particular divergence between the two proteins (Fig. 4c): The first includes the N-terminal region of 
ABCB4 including TM1, the second includes the linker region between NBD1 and TMD2, and the third 
includes the extracellular loops. We therefore generated three chimeras: In ABCB4[B1-N-term], we 
replaced the N-terminus, the first elbow helix, TM1 and the first extracellular loop of ABCB4 with the 
corresponding segments of ABCB1. In ABCB4[B1-Linker], the linker region of ABCB4 was replaced by that 
of ABCB1. In ABCB4[B1-ExLoops], the extracellular loops EL1, EL3, EL4, and EL6 were spliced into ABCB4 
(EL2 and EL5 are identical in the two transporters). The three chimeras were then tested for their ability 
to extrude PC after transient transfection into HEK cells. Given that some of the resulting constructs had 
different expression levels compared to WT ABCB4, the observed activities were normalized by the 
amounts of solubilizable protein in the plasma membranes (Supp. Fig. 7a). 
In a baseline experiment, we found that WT ABCB4 extruded far greater amounts of PC than WT ABCB1 
(Fig. 4d), and this difference was enhanced by the addition of taurocholate, similarly to the stimulation 
found using the stable cell line (Fig. 1b). We further found that both the ABCB4[B1-N-term] and the 
ABCB4[B1-Linker] construct had only minor effects on the activity of ABCB4 (Fig. 4d) or on the amount of 
protein that could be extracted from plasma membranes (Supp. Fig. 7a). However, the construct 
ABCB4[B1-ExLoops] displayed significantly lower extrusion activity than WT ABCB4, closer to the level of 
ABCB1, despite the much larger amounts of this construct expressed on the cell membrane. A residual 
extrusion activity remains, suggesting that the extracellular loops alone cannot fully account for the 
differences between ABCB4 and ABCB1.  
We then considered a potential role of the hydrophobic transmembrane cavity. This cavity has been 
observed in many inward-facing, outward-facing, and occluded ABC transporter structures, including 
ABCB127, and was identified as the binding site of the ABCB1 inhibitor zosuquidar44 and of the substrate 
paclitaxel45. Considering the occluded, drug-binding state of ABCB1, residues shown to interact with 
substrates and inhibitors are highly conserved between ABCB4 and ABCB1. Of twenty zosuquidar-binding 
residues, only three are not fully conserved in ABCB4 (V985, H989 and A990, Supp. Fig. 7b, Supp. Fig. 7d). 
We generated a triple mutant of ABCB4 (V985M, H989Q and A990V), thus converting the ABCB4 cavity to 
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be identical to that of ABCB1 for all the positions identified as Zosuquidar binding in ABCB1. The resulting 
ABCB4 variant revealed greatly reduced PC extrusion activity (Fig. 4d), comparable to exchanging all the 
extracellular loops (ABCB4[B1-ExLoops]). The effects of these residue exchanges could in principle be 
allosteric rather than direct, and rather than specifically disabling PC transport they could disable 
transporter function in general. However, our other chimeras show that large stretches of ABCB1 residues 
can be introduced into ABCB4 with little or no effect on PC extrusion, consistent with the hypothesis of a 
shared overall transport mechanism between ABCB1 and ABCB4 residues in general.  Furthermore, for the 
triple mutant construct (V985M, H989Q and A990V), all nearby residues are conserved between ABCB4 
and ABCB1, which makes it highly unlikely that the exchange is detrimental to transporter fold or general 
mechanics. A more likely interpretation of the data is therefore that these residues have a direct role in 
PC transport and that ABCB4 and ABCB1 both use central cavities for transporting their substrates. 
 
Proposed transport mechanism of ABCB4 
Because the residues V985, H989 and A990 proved critical for ABCB4 activity, we considered their side 
chain interactions in our ABCB4 structure. While the residues appear to contribute to an extensive network 
of interactions between the TM helices in the observed conformation, it is not evident that these 
interactions would be disturbed by either of the mutations V985M, H989Q or A990V (Supp. Fig. 7b). We 
therefore considered possible roles in other steps or states of the transport cycle. We generated homology 
models of ABCB4  (Fig. 5a) in distinct conformations, using as templates the outward-open state of the 
bacterial multidrug exporter Sav1866 (PDB: 2HYD58), the occluded state of human-mouse chimeric ABCB1 
(PDB: 6QEE45), and the inward-open state of mouse ABCB1 (PDB: 4M1M43). In the predicted outward-open 
state, the side chains of the three residues V985, H989 and A990 line the outward-facing cavity and are 
accessible from the extracellular medium. In the predicted occluded state, they line the surface of the 
occluded cavity (Fig. 5c). Because these three residues were well-ordered not only in our ABCB4 structure 
but also in the ABCB1 structure that served as the modelling template (EMD-4281, Supp. Fig. 7d), the 
confidence in the modelled ABCB4 conformation is high. Finally, in the inward-open state, the three 
residues are accessible from the intracellular medium and from the inner leaflet of the lipid bilayer (not 
shown). The three residues are thus ideally positioned contribute to substrate binding and release. This is 




ATP-driven translocation or flipping of phospholipids is an essential but mechanistically poorly understood 
process. Our results suggest that in contrast to mechanisms proposed for other phospholipid transporters, 
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ABCB4 transports PC to the outer membrane leaflet by an alternating access27,67 mechanism, with the 
entire phospholipid molecule entering and leaving a central translocation pathway. This is distinct from 
the ‘credit card swipe’ mechanism proposed for active phospholipid transport by P4-ATPases68, where the 
head group of the lipid is moved into or along a hydrophilic groove on the lipid-facing protein exterior 
while the hydrocarbon tail remains in the lipid bilayer. It is also distinct from the mechanism proposed for 
passive transport by scramblases of the TMEM16, which is similar to the credit card swipe model but where 
local distortions of the lipid bilayer geometry strongly contribute to the lowering of the activation barrier69-
72. Yet another ABC phospholipid transporter, ABCA1, may employ an ‘outward only’ mechanism, similar 
to that employed by the lipid-linked oligosaccharide transporter PglK32, which has as much in common 
with credit card swipe as with alternating access, though the details of the proposed ‘lateral access’ 
scheme for ABCA1 are not yet clear33.  
We propose that ABCB4, in contrast, employs an alternating access mechanism, similar to that proposed 
for multidrug export by ABCB1 but with at least two key adaptations: First, we conclude that the 
extracellular loops have a critical role in facilitating PC transport, potentially by assisting the reorientation 
of the substrate into the outer leaflet, though we cannot rule out an allosteric mode of action. Second, we 
show that although the residues lining the proposed translocation pathway of ABCB4 are very similar to 
that of ABCB1, the differences between these cavities are crucial for PC export in ABCB4. We propose that 
the most likely explanation for this is that the central cavity is facilitating PC transport directly. The finding 
that most of the cavity-forming residues are identical between ABCB4 and ABCB1 is consistent with reports 
that ABCB4 can recognize and transport some ABCB1 substrates. An alternating access mechanism has 
previously been proposed for MsbA-catalyzed transport of the lipid-A-core, a much larger molecule than 
phosphatidylcholine31. While the vanadate-trapped structure of MsbA resembles the nucleotide-bound 
states of ABCB4 and ABCB146, MsbA likely requires a different occluded state to accommodate the much 
larger substrate, as the inward open MsbA structure shows the substrate extending well into the 
cytoplasmic domain. This makes the proposed mechanism for ABCB4 unique in that it consists of relatively 
subtle adaptations tuning a general multi-drug export mechanism for phospholipid transport. 
In conclusion, our results not only provide the first visualization of human ABCB4, they also provide insight 
into how a general ABC transporter architecture is adapted to different classes of substrates and different 
selectivity profiles. It sets the stage for studying drug-induced inhibition of ABCB4 and to delineate the 
precise lipid transport cycle by biophysical techniques. 
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Generation of expression constructs. A DNA sequence coding for the predominant isoform of ABCB4 
(UniProt ID P21439-2) was designed with regularly spaced silent restriction sites, codon optimized for 
expression in human cells and generated synthetically (Thermo Fischer Scientific). All subsequent 
modifications of the sequence, including the introduction of the point mutations E558Q and E1200Q, were 
performed using synthetic gene fragments (Integrated DNA technologies). Restriction enzymes and T4 
DNA ligase were purchased from NEB. Constructs for transient expression in HEK293 cells were cloned, 
following the strategy described above, into an expression vector containing the pXLG gene expression 
cassette in a pUC57 vector. Stable cell lines for expression were generated using the Flp-In T-Rex system 
(Thermo Fisher Scientific), according to the manufacturer’s guidelines. All expression constructs included 
a C-terminal eYFP/rho-ID4 tag and a preceding 3C protease cleavage site. ABCB4-ABCB1 chimeras were 
constructed with ABCB1 residues exchanged into ABCB4 as follows: ABCB4[B1-N-term]: residues 1-109. 
ABCB4[B1-Linker]: residues 630-716. ABCB4[B1-ExLoops]: residues 92-109, 324-334, 737-753 and 963-
971. 
Protein production and purification. Flp-In T-Rex 293 cells stably expressing ABCB4 or ABCB4[EQ] were 
adapted to grow in suspension culture in EX-Cell 293 serum-free medium (Sigma-Aldrich) supplemented 
with 100 Units/ml Penicillin, 100ug/ml Streptomycin and 6mM Glutamine. Cells were maintained at 37°C 
and shaking at 100rpm (Kuhner) at 6% CO2 and 80% humidity. Expression was induced by addition of 
0.25ug/ml tetracycline (AppliChem). Cells were harvested after 48-72 hours by spinning at 6000 rpm in an 
F-10S rotor (Thermo Scientific) for 10 min. All subsequent steps were performed at 4°C or on ice unless 
otherwise specified. Cell pellets were resuspended in 150mM NaCl, 20mM HEPES pH 7.5 and 20% glycerol 
(4ml/g pellet) supplemented with cOmplete EDTA-free protease inhibitor cocktail tablets (Roche) and 
homogenized using a dounce homogenizer. Protein was solubilized by addition of a mixture of 1% dodecyl 
maltopyranoside (DDM) and 0.2% cholesteryl hemisuccinate (CHS) and incubation on a roller shaker for 
90 minutes. Cellular debris and non-solubilized membrane fragments were spun down for 30 min at 35000 
rpm in a Type 45-Ti rotor (Beckmann). The supernatant was applied to sepharose-coupled Rho-ID4 
antibody (University of British Columbia) and incubated for at least 1 hour. Beads were washed four times 
with ten column volumes (CV) of buffer (as during resuspension) supplemented with 0.02%/0.004% 
DDM/CHS. Subsequently, beads were incubated for at least one hour with 3 CV buffer supplemented with 
a 1:10 (w/w) ratio of 3C protease to protein. Cleaved protein was eluted through Ni-NTA beads (Qiagen) 
for capturing the His-tagged protease. Protein concentrations in detergent micelles were measured by 
absorbance at 280nm using a NanoDrop 2000c spectrophotometer (Thermo Fischer Scientific) 
Nanodisc reconstitution. A mixture of liver polar lipids from (LPL) from Avanti Polar lipids and CHS (4:1 
w/w) were solubilized in 0.5% DDM/CHS and mixed with nanodisc scaffold protein MSP1D1 and ABCB4 in 
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a stoichiometry of 20:1:0.2, diluted to reduce glycerol concentration below 4% and incubated 15min at 
RT. CHS was chosen over cholesterol as this was necessary to fully solubilize the lipid mix prior to 
reconstitution. However, it is noted that LPL already contains 5% cholesterol. Nanodisc formation was 
induced by removing detergent with Bio-Beads (Bio-Rad) for 2H at room temperature. Samples were 
concentrated on 100k MWCO centrifugal filter. Protein concentrations in nanodiscs were measured by gel 
densitometry analysed in imageJ73. 
ATPase activity assays. Hydrolysis of ATP was measured with a molybdate based colorimetric assay74. 5-
10ug of protein in detergent (150mM NaCl, 20mM HEPES pH 7.5, 20% glycerol and 0.02%/0.005% 
DDM/CHS) or 3-7ug embedded in LPL:CHS nanodiscs (150mM NaCl and 20mM HEPES pH 7.5) were used 
per reaction. Assays were started by addition of ATP in the presence of 10mM MgCl2, incubated for 30-
40min at 37°C, and stopped by addition of 6% SDS. Control reactions in the absence of MgCl2 were run in 
duplicate and subtracted as background for each data point. Reactions were done in triplicate and 
repeated with different batches of protein and reagents. Results were analysed in GraphPad Prism 7. 
PC efflux assays. Flp-In T-Rex 293 cells carrying a gene for stable expression of ABCB4 or ABCB4[EQ], or 
HEK293T cells, were grown in adherent culture plates in DMEM medium supplemented with 10% FBS and 
penicillin/streptomycin at 37 °C at 6% CO2 in a humidified incubator. Flp-In T-Rex cells were induced to 
expression by exchange into DMEM supplemented with 2% FBS, penicillin/streptomycin and 0.2µg/ml 
tetracycline. HEK 293T cells were transiently transfected in DMEM supplemented with 2% FBS and 
penicillin/streptomycin by dropwise addition of a mixture of DNA and branched polyethylenimine (1:2.5 
ratio). After 24H expression, cells were washed with PBS and medium was exchanged to DMEM 
supplemented with 0.02% BSA, with or without 0.1mM Na-taurocholate. After a further 18H, medium was 
harvested, lipids were extracted with a 40:20:1 methanol:chloroform:0.1M KCl mixture and dried under 
argon. PC content was analyzed with Phosphatidylcholine Assay Kit (SIGMA). Total cellular protein was 
measured with Pierce BCA Protein Assay Kit (Thermo). Curve fitting was done in GraphPad Prism 7. At least 
three experiments were performed in duplicate for each sample, except for the ABCB4[EQ] stable cell line 
where two experiments were performed in duplicate. To estimate expression levels, DDM/CHS solubilized, 
fluorescently labelled protein was extracted from pelleted cells and analysed on a TSKgel G4000SWXL 
column at 0.5ml/min (0.4ml/min for protein extracted from stably expressing cells) in 150mM NaCl, 20mM 
HEPES pH 7.5 and 0.02%/0.004% DDM/CHS. Results from cells transiently expressing different constructs 
were normalized relative to expression level of each construct and was shown relative to results for ABCB4 
without added NaTc, measured on the same batch of cells. Results from stable cell lines were normalized 
according to total cellular protein. 
EM sample preparation. WT ABCB4 or ABCB4[EQ] reconstituted into LPL:CHS nanodiscs was loaded on a 
TSKgel G3000SWxl column (Tosh Biosciences) and run in a 150mM NaCl, 20mM HEPES pH 7.5 buffer at 
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0.4ml/min. The peak fraction, at ~0.5mg/ml, was equilibrated with either 5mM ATP and 5mM MgCl2 
(ABCB4[EQ]) or 4mM ATP, 10mM MgCl2 and 4mM Na3VO4 (WT ABCB4) before blotting for 3 seconds on 
glow-discharged Quantifoil carbon grids (1.2/1.3µM, 300 mesh, copper) using a Vitrobot Mark IV (FEI). 
Grids were plunge-frozen into a liquid ethane-propane mixture cooled by liquid nitrogen.  
Cryo-EM data acquisition and processing. Grids were imaged with a Titan Krios (FEI) electron microscope 
operating at 300 keV and equipped with a Gatan Quantum LS energy filter (GIF) and a Gatan K2 Summit 
direct electron detector. Image stacks comprising 40 Frames were collected in super resolution mode at a 
nominal magnification of 165000x. 
For data collection using the ABCB4[EQ] sample with ATP and Mg2+ an estimated dose rate of 1.7 electrons 
per square angstrom per frame was applied. Defocus was set to vary from −0.5 to −3μm. A total of 6865 
micrograph stacks were motion-corrected, dose-weighted and two-fold Fourier-cropped to a calibrated 
pixel size of 0.84Å in MotionCor275 (Supp. Figure 3a). Contrast Transfer Function was estimated with 
gCTF76. From 5124 micrographs selected after CTF estimation, a total of 1815578 particles were picked in 
RELION77,78 using a 3D template generated from an initial model, which in turn was calculated from 
particles picked by the Laplacian-of-Gaussian based autopicking procedure on all selected micrographs. 
After two rounds of 2D classification, initial 3D classification was performed with three classes. A majority 
of particles (71%) located to closed conformations and a minority of particles into a conformation with 
more separation between the NBDs. For particles belonging to the more open class processing did not 
improve the density beyond a reported 8Å resolution (Supp. Fig. 3b). Most likely this class contains 
particles with a spectrum of NBD separation. Particles from the highest quality of the closed classes were 
refined using RELION’s 3D auto-refine procedure and post processed to 3.4Å. Subsequent 3D classification 
into two classes in RELION resulted in a 3D class containing the majority of particles (193929 particles) and 
which had slightly stronger signal for the NBDs and helices and slightly weaker signal for the nanodisc 
compared to the other class. Refinement and postprocessing of this class yielded a 3.3Å map. CTF 
refinement, Bayesian Polishing within RELION and exclusion of the nanodisc region from the map yielded 
the final 3.2Å resolution structure, as estimated based on the FSC cutoff criterion of 0.143 (Supp. Fig. 3c). 
This map was subsequently used for model building. 
For data collection using the WT ABCB4 sample with ATP, MG2+ and NA3VO4 (Supp. Fig. 2b-d) an estimated 
dose rate of 1 electron per square angstrom per frame was applied. Defocus was set to vary from −1 to 
−3μm. A total of 2630 micrograph stacks were motion-corrected, dose-weighted and two-fold Fourier-
cropped to a calibrated pixel size of 0.84Å in MotionCor2 and the Contrast Transfer Function was estimated 
with gCTF. From 1421 micrographs selected after CTF estimation, a total of 215840 particles were picked 
using Gautomatch (http://www.mrc-lmb.cam.ac.uk/kzhang/) and processed in cryoSPARC79. 138724 
particles were selected after one round of 2D classification. Heterogeneous refinement with three classes 
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produced two classes with greater NBD separation while the class with the greatest number of particles 
(38%, 53171 particles) showed less NBD separation. Further refinement did not lead to improved map 
quality (Supp. Fig. 2d).   
Model building and refinement. The B-factor sharpened map at 3.2Å was used for model building in Coot80 
with the quality of density in most of the TMDs and NBDs allowing for de-novo model building  (Supp. Fig. 
4). A model was built for ABCB4 in the nucleotide-bound state (Fig. 2a-b) and comprising residues 42-84, 
105-629 and 692-1252. For both residues H589 and H1231 density indicated the presence of two 
orientations also affecting surrounding residues and in each case the orientation with the strongest density 
was built into the model. Coordinate refinement was performed in Phenix81 with geometric and secondary 
structure restraints. Residue numbers in the paper are based on human ABCB4 isoform 2 (UniProt ID 
P21439-2). 
Homology modelling. Homology models were generated in SWISS-MODEL82 based on templates 2HYD, 
6QEE and 4M1M. Residues 1-40 and 630-691 were excluded from the final models as good templates for 
these regions were unavailable. 
Figure preparation. Images of models and maps were prepared in UCSF Chimera57 and PyMOL (The PyMOL 






Figure 1. Functional characterization of ABCB4. a) Schematic of PC extrusion in the bile canaliculi. PC 
indicates phosphatidylcholine, BS bile salt and CHL cholesterol. Tight junctions are indicated in brown, 
between hepatocytes. Yellow rectangles and triangles indicate complementary sides of nucleotide binding 
sites. b) PC extrusion by WT ABCB4 and ABCB4[EQ] stably expressed in Flp-In T-REx 293 cells. Filled bars 
indicate extrusion in the presence of 1mM sodium taurocholate while unfilled bars indicate extrusion in 
the absence of taurocholate. Error bars indicate S.E.M of the data points shown. Insert shows schematic 
of PC extrusion from HEK293T cells expressing ABCB4. TC indicates taurocholate, BSA indicates bovine 
serum albumin. c) SEC profile of purified WT ABCB4 reconstituted into LPL:CHS nanodiscs. The inset shows 
sample loaded on SDS-PAGE, with bands for ABCB4 (theoretical MW 141kDa) and the nanodisc scaffold 
protein MSP1D1 (theoretical MW 24.7kDa). d) ATPase activity of ABCB4 in a lipid environment (LPL:CHS 
nanodiscs, black squares, curve fitted to Michaelis-Menten kinetics in blue), and in detergent (DDM/CHS 
micelles, black triangles, red curve). Data points indicate means of three independent measurements, 
error bars indicate S.E.M. e) ATPase activity of the ABCB4[EQ] double mutant in nanodiscs (black squares, 
blue curve) and DDM/CHS (black triangles, red curve). Data points indicate means of three independent 

























Figure 2. Structure of human ABCB4. a) Topology diagram of ABCB4. Transmembrane helices are 
numbered. Elbow helices (E1 and E2) are indicated as are the coupling helices (C1 and C2) and the NBDs. 
Stretches of residues not built in the final model are indicated with dotted lines. Predicted N-glycosylation 
sites indicated in green, ATP-binding sites in yellow. b) Cartoon representation our ABCB4 model with the 
first half of the sequence, including transmembrane helices (TMHs) 1-6 and NBD1, coloured cyan and the 
second half, including TMHs7-12 and NBD2, coloured in orange. Nucleotides are represented as black 
sticks, Mg2+ as a yellow sphere and cholesterol as green sticks. c) Surface representation of ABCB4 oriented 
as in the right side of panel b) with view clipped to a thickness of ~2Å around the centre of the protein. 
The hydrophilic cavity is indicated by dashed magenta rectangle. d) The central cavity (magenta) and the 





Figure 3. Nucleotide binding to ABCB4. a) Cartoon representation of the NBDs viewed from the direction 
of the membrane toward the cytoplasm with inserts showing density of nucleotides and selected residues 
for each site,  contoured at σ =10 and carved at a distance of 2Å. b) The two half-NBDs are shown 
superimposed upon each other, with interacting nucleotides and selected residues shown in stick format 
and magnesium as a yellow sphere. Colouring of atoms follows panel a), with carbon atoms coloured 





Figure 4. Functionally impairing mutants and chimeras of ABCB4. a)  Disease causing mutations 
functionally impairing ABCB4 are shown in black on a ribbon representation of ABCB4. ATP shown in red. 
b) Disease causing mutations impairing maturation or trafficking of ABCB4 are shown in black. c) Ribbon 
representation of ABCB4 with the regions of greatest sequence variability between ABCB4 and ABCB1 
indicated as cartoons in respectively Green (ABCB4[B1-N-term]), Red (ABCB4[B1-Linker]) and Blue 
(ABCB4[B1-ExLoops]). Dashed lines indicate residues not resolved in the present structure. d) PC extrusion 
by ABCB4-ABCB1 chimeras in transiently transfected HEK cells with (solid bars) and without (hollow bars) 
stimulation of extrusion by 0.1mM NaTc. Error bars indicate S.E.M. the data points shown. Results are 
normalized to according to amount of transporter extracted from membranes (Supp. Fig. 4a) and shown 





Figure 5. The structure of ABCB4 in the context of the transport cycle. a) Our structure of the closed 
conformation of ABCB4 (4) is shown next to homology models based on (1) inward open ABCB1 (PDB 
4M1M), (2) inward occluded ABCB1 (PDB 6QEE) and (3) outward open Sav1866 (PDB 2HYD). b) Predicted 
occluded state of ABCB4, with residues predicted to interact with compounds bound in the hydrophobic 
cavity shown as sticks. Viewed from the direction of the canaliculus. c) The nucleotide bound state of 




















Supplementary Figure 1. A-b) FSEC profiles of eYFP-labeled protein extracted by DDM/CHS from pellets 
of WT ABCB4 expressing Flp-In T-Rex 293 cells collected after harvesting of media for extrusion 
experiments. Black lines indicates signal from cell with expression induced by addition of tetracycline, red 
lines indicates signal from uninduced cells. Samples were loaded on a TSKgel G4000SWXL column at 
0.4ml/min. a) Signals from cells expressing wt-ABCB4). B) Signals from cells expressing ABCB4[EQ]. c-f) SEC 
profiles of purified ABCB4 reconstituted into LPL:CHS nanodiscs and run on a a TSKgel G3000SWXL column 
at 0.4ml/min. c) ABCB4[EQ] d) Reinjection of the peak from c) at around 18min. e) wt-ABCB4 with 
















Supplementary Figure 2. Cryo-EM data processing of vanadate-trapped wt-ABCB4. a) ATPase activity of 
vanadate-trapped wt-ABCB4 (black squares and curve) shown relative to the activity without vanadate 
(dashed blue line, curve from fig. 1d). Data points indicate means of three independent measurements, 
error bars represent S.E.M. b) Representative motion-corrected micrograph of ABCB4 at a nominal 
magnification of 165kx and a defocus of 2.7 µm. c) Representative 2D classes from cryoSPARC. d) 
















Supplementary Figure 3. Cryo-EM structure determination of nucleotide-bound ABCB4. a) Representative 
motion-corrected micrograph of ABCB4 at nominal magnification of 165kx and a defocus of 2.2µm. 
Representative 2D classes from RELION are shown to the left. b) RELION processing workflow c) Local 
resolution calculated with ResMap in RELION and presented on the sharpened EM map, colour coded 
according to the scale bar next to the density. d) Fourier shell correlation curves from RELION. e) 

















Supplementary Figure 4. The model of nucleotide-bound ABCB4 built according to density. Contour level 
is set at σ =5 and density is carved at a distance of 2Å. a) Density contours from b-factor sharpened map 
is shown for all six helix pairs as well as the NBDs. b) Density contours shown around central slices of the 



















Supplementary Figure 5. Alignment between human ABCB4 and ABCB1. Sequence alignment was done 
in T-Coffee and layout was done using the ENDscript server. ABCB1 residues interacting with inhibitor 
zosuquidar are highlighted in yellow. Residues exchanged in chimeric constructs are indicated with bars 
coloured as in Fig. 4b.   
 
 
Supplementary Figure 6. Stereo representations from PyMOL of disease causing mutants of ABCB4 
mapped onto the closed conformation described in this work. A) Mutations affecting function. B) For 
clarity, panel a of main figure 4 is shown with residue identities indicated. C) Mutations affecting 














Supplementary Figure 7. a) ABCB4 and ABCB1 chimeras reveal important residues. The amounts of 
protein extracted with DDM/CHS from experiments shown in Fig. 4d are indicated by luminescence units 
relative to wt-ABCB4.  Main peak heights (peak at 20 min) were used to normalize results of the extrusion 
assays. b) The three positions mutated in the 3M construct (V985M, H989Q and A990V) are shown in a 
model of the ATP-Mg2+ bound ABCB4 in stick representation, and residues within 4Å are shown in line 
representation. c)  Residues V985, H989 and A990 and nearby residues on TMH12, from the model of 
ABCB4 in the closed conformation, are shown with associated density contoured at a level of σ =6.5 and 
carved at a distance of 2Å from residues. d) Residue positions corresponding to those in a) are shown on 
the previously published model of human-mouse chimeric ABCB1 bound to the inhibitor zosuquidar44, 
used for homology modelling, with density from the associated map contoured at a level of σ =6.5 and 
carved at a distance of 2Å from residues.  
Cryo-electron microscopy data collection and processing 
Microscope FEI Titan Krios 
Voltage (keV) 300 
Camera Gatan K2-Summit 
Energy Filter Gatan Quantum-LS (GIF) 
Pixel size (Å) 0.84 
Defocus range (µm)  (-0.5) - (-2.5) 
Number of micrographs 6865 
Particles in final class 193929 
Resolution (Å) 3.2 
Sharpening B-factor (Å2) -85.4 
  
Coordinate refinement and validation 
Number of protein atoms (non-H) 8741 
Number of ligand atoms (non-H) 287 
RMSD bonds (Å) 0.009 
RMSD angles (°) 1.034 
Ramachandran favored (%) 97.24 
Ramachandran Allowed (%) 2.76 
Ramachandran Disallowed (%) 0 
All-atom clashscore 3.49 
Rotamer outliers (%) 0.33 
 
Supplementary Table 1. Overview of EM data collection and coordinate refinement with statistics from 
MolProbity in Phenix.   
 



















T34M 58.3% ± 6.6%9 ~100%9 BC, DILI, ICP, LPAC9, 84 
R47G 32.2% ± 5.6%9 ~100%9 LPAC84, 85 
D243A 56% ± 0.16%14 ~100%14 BC86 
A286V ~0%10 ~100%10 LPAC, PFIC389 
S346I ~5%12*** ~100%12*** PFIC389 
K435T ~0%14 ~100%14 BC86 
G535D ~0%14, ~20% 13*** ~100%14 BC, CG, ICP88 
P726L ~5%12*** ~100%14 PFIC389 
A737V 53%15** ~100%15 PFIC389 
T775M ~75%12*** ~100%12*** PFIC389 
G954S ~60%12*** ~100%12*** PFIC389 
S1076C ~10%13*** ~100%13 PFIC392 
S1176L ~5%13*** ~100%13 LPAC13 
G1178S ~2%13*** ~100%13 LPAC13 
A1193T 61%15** ~100%15 PFIC389 



















S320F ~100%10 50.1%10 DILI90, ICP90, LPAC89, PFIC389 
F357L ~40%12*** ~25%12*** PFIC389 
A364V 51%15** 30%15 PFIC389 
I490T N.D.14 6%14 CC, CG, JD, PR87 
G536R ~2%13 ~55%13*** ICP93 
I541F ~10%12*** Only immature form expressed12 PFIC389 
R545C N.D.14 17%14 SC86 
L556R ~10%12*** Only immature form expressed12 PFIC389 
Q855L ~40%12*** ~60%12*** PFIC389 
S978P N.D.14 22%14 CC, ICP, LPAC87 
A953D 29%10 16.3%10 PFIC391 
Supplementary Table 2. Overview of disease causing mutations of ABCB4 referred to in this paper. BC: 
Biliary Cirrhosis, DILI: Drug-induced Liver Injury, ICP: Intrahepatic Cholestasis of Pregnancy, LPAC: Low-
Phospholipid–Associated Cholelithiasis, SC: Sclerosing Cholangitis, CC: Cholangiocarcinoma, CG: 
Cholesterol Gallstones, JD: Jaundice, PR: Pruritus, PFIC3: Progressive Familial Intrahepatic Cholestasis 
Type 3, N.D: Not Detected. *: Normalized to expression level relative to WT. **: Value refers to ATPase 
activity rather than transport. ***Value estimated visaully from graph in reference.  
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